Human umbilical cord (UC) can be obtained during the perinatal period as a result of preterm, term, and postterm delivery. In this protocol, we describe the isolation and characterization of UC-derived mesenchymal stem cells (UC-MSCs) from fetuses/infants at 19-40 weeks of gestation.
Mesenchymal stem cells (MSCs) have considerable therapeutic potential and attract increasing interest in the biomedical field. MSCs are originally isolated and characterized from bone marrow (BM), then acquired from tissues including adipose tissue, synovium, skin, dental pulp, and fetal appendages such as placenta, umbilical cord blood (UCB), and umbilical cord (UC). MSCs are a heterogeneous cell population with the capacity for (1) adherence to plastic in standard culture conditions, (2) surface marker expression of CD73+/CD90+/CD105+/CD45–/CD34–/CD14–/CD19–/HLA-DR– phenotypes, and (3) trilineage differentiation into adipocytes, osteocytes, and chondrocytes, as currently defined by the International Society for Cellular Therapy (ISCT). Although BM is the most widely used source of MSCs, the invasive nature of BM aspiration ethically limits its accessibility. Proliferation and differentiation capacity of MSCs obtained from BM generally decline with the age of the donor. In contrast, fetal MSCs obtained from UC have advantages such as vigorous proliferation and differentiation capacity. There is no ethical concern for UC sampling, as it is typically regarded as medical waste. Human UC starts to develop with continuing growth of the amniotic cavity at 4-8 weeks of gestation and keeps growing until reaching 50-60 cm in length, and it can be isolated during the whole newborn delivery period. To gain insight into the pathophysiology of intractable diseases, we have used UC-derived MSCs (UC-MSCs) from infants delivered at various gestational ages. In this protocol, we describe the isolation and characterization of UC-MSCs from fetuses/infants at 19-40 weeks of gestation.
Mesenchymal stem cells (MSCs) are originally isolated and characterized from bone marrow (BM)1,2 but can also be obtained from a wide variety of tissues including adipose tissue, synovium, skin, dental pulp, and fetal appendages3. MSCs are recognized as a heterogeneous cell population that can proliferate and differentiate into adipocytes, osteocytes, and chondrocytes. In addition, MSCs possess the ability to migrate to sites of injury, suppress and modulate immune responses, and remodel and repair injury. Currently, MSCs from different sources have attracted growing interest as a source for cell therapy against a number of intractable diseases, including graft-versus-host disease, myocardial infarction, and cerebral infarction4,5.
Although BM is the most well-characterized source of MSCs, the invasiveness of BM aspiration ethically limits its accessibility. Proliferation and differentiation capacity of MSCs obtained from BM generally decline with the age of the donor. In contrast, fetal MSCs obtained from fetal appendages such as placenta, umbilical cord blood (UCB), and umbilical cord (UC) have advantages including less ethical concerns regarding sampling and robust proliferation and differentiation capacity6,7. Among fetal appendages that are usually discarded as medical waste, UCB and UC are considered a fetal organ, while placenta is considered fetomaternal. In addition, placenta and UCB need to be sampled and collected at the exact moment of newborn delivery, whereas placenta and UC can be collected and processed after newborn delivery. Accordingly, UC is a promising MSC source for cell therapy8,9.
Human UC starts to develop with progressive expansion of the amniotic cavity at 4-8 weeks of gestation, continues to grow until 50-60 cm in length, and can be isolated during the whole period of newborn delivery10. To gain insight into the pathophysiology of intractable diseases, we use UC-derived MSCs (UC-MSCs) from infants delivered at various gestational ages11,12. In this protocol, we describe how to isolate and characterize UC-MSCs from fetuses/infants at 19-40 weeks of gestation.
The use of human samples for this study was approved by the ethical committee of Kobe University Graduate School of Medicine (approval no. 1370 and 1694) and conducted in accordance with the approved guidelines.
1. Isolation and Culture of UC-MSCs
NOTE: UC-MSCs have been successfully isolated, cultured, and expanded (more than passage number 4) from more than 200 UCs subjected to this protocol. Among more than 200 UCs, 100% have shown successful UC-MSC isolation, less than 5% have shown accidental contamination, less than 15% have shown growth arrest, and more than 80% have shown successful UC-MSC expansion.
2. Surface Marker Expression of UC-MSCs
3. Trilineage Differentiation of UC-MSCs
The procedures from UC collection to MSC culture are summarized in Figure 1. UC of approximately 5-10 cm in length can be collected from all newborns delivered by cesarean section. UC starts to develop at 4-8 weeks of gestation and continues to grow until 50-60 cm in length, as shown in Figure 2. There are two arteries (A), one vein (V), cord lining (CL), and Wharton's Jelly (WJ) in UC, as depicted in Figure 3 and Figure 4. UC-MSCs can be isolated from all cord regions or whole cord13. Because UC from infants with early gestational ages is fragile and difficult for dissection into a single cord region, UC-MSCs are isolated from whole cord11,12. There are several methods to isolate MSCs from UC, which include the explant method14 and enzymatic digestion method15, plus their derivatives16. Due to the longer culture cycle, lower yield, and earlier proliferation arrest associated with the explant method17,18, UC-MSCs are cultured by enzymatic digestion method as illustrated in Figure 5 and Figure 6.
The minimal criteria for defining MSCs are established by the ISCT and include their surface marker characterization19. To determine surface marker expression, UC-MSCs from preterm and term infants are incubated with appropriate PE-conjugated antibodies and analyzed by flow cytometry. They are positive for MSC signature markers (CD73, CD90, CD105) but negative for monocyte/macrophage (CD14), endothelial (CD34), hematopoietic (CD19, CD45), and major histocompatibility complex (HLA-DR) markers, as shown in Figure 7.
According to the ISCT criteria19, MSC must possess mesodermal differentiation capacity assessed by a trilineage differentiation assay. To evaluate trilineage differentiation capacity, UC-MSCs from preterm and term infants are induced to differentiate into osteocytes, adipocytes, and chondrocytes under standard in vitro differentiation conditions. As shown in Figure 8, they are well-differentiated into all three types of mesodermal cells.
Figure 1: Schematic diagram of isolation and culture of UC-MSCs. Step 1. 5-10 cm of UC aseptically collected from placental tissue. Step 2. Purified enzyme blend-digested UC pieces. Step 3. Culture of UC-MSCs at 37 °C in a 5% CO2 incubator. Step 4. Attached UC-MSCs appeared at 3 days after initial plating. Step 5. Subculture of UC-MSCs. Please click here to view a larger version of this figure.
Figure 2: UC from fetuses/infants delivered at various gestational ages. UCs from fetuses/infants at 19-38 weeks of gestation are shown. The size of UC increases with gestational age. Scale bars = 8 cm. Please click here to view a larger version of this figure.
Figure 3: Sectional view of UC from preterm and term infants. There are two arteries (A), one vein (V), cord lining (CL), and Wharton's Jelly (WJ) in UC from preterm and term infants. The sizes of these tissues vary with gestational ages. Scale bars = 2 mm. Please click here to view a larger version of this figure.
Figure 4: Anatomy of UC. (A) 5 cm of UC from term infant. (B) Cross section of UC. (C) Partially dissected UC. There are two arteries (A), one vein (V), cord lining (CL), and Whalton's Jelly (WJ). UC from infants of earlier gestational ages is particularly fragile and difficult to be dissected. Please click here to view a larger version of this figure.
Figure 5: UC dissection using purified enzyme blends. (A) 5-10 cm of UC. (B) 2-3 mm pieces of UC. (C) Purified enzyme blend-digested UC pieces. Please click here to view a larger version of this figure.
Figure 6: Morphology of UC-MSCs from preterm and term infants. (A and E) UC-MSCs at passage number 1 (P1) before the replacement of culture medium (A: X40; E: X200). (B and F) UC-MSCs at P1 after the replacement of culture medium (B: X40; F: X200). (C and G) UC-MSCs at P3 (C: X40; G: X200). (D and H) UC-MSCs at P5 (D: X40; H: X200). Scale bars = 50 µm. Please click here to view a larger version of this figure.
Figure 7: Surface marker expression of UC-MSCs from preterm and term infants. CD73/CD90/CD105-positive and CD14/CD19/CD34/CD45/HLA-DR-negative phenotypes are found in UC-MSCs from both preterm (22 weeks gestation) and term (37 weeks gestation) infants. Please click here to view a larger version of this figure.
Figure 8: Trilineage mesenchymal differentiation of UC-MSCs from preterm and term infants. UC-MSCs from preterm (22 weeks gestation) and term (37-40 weeks gestation) infants are differentiated into adipocyte (visualized by oil red O), osteocyte (visualized by alizarin red S), and chondrocyte (visualized by toluidine blue). Images were taken at 200x. Scale bars = 50 µm. A part of this figure has been adapted from Iwatani et al.11. Please click here to view a larger version of this figure.
MSCs can be isolated from a variety of tissues and are heterogeneous population of cells that do not all express the same phenotypic markers. Here, we outlined a protocol that guides the collection and dissection of UC from preterm and term infants and enables isolation and culture of UC-MSCs. Following this protocol, we have successfully isolated UC-MSCs that fulfill the ISCT criteria19 from fetuses/infants delivered at 19-40 weeks of gestation and demonstrated that they represent some aspects of intractable disease pathophysiology during prenatal development11,12.
In BM-derived MSCs (BM-MSCs), younger donor-derived BM-MSCs generally show greater proliferative and differentiative potential than older counterparts and hold more potential for cell therapy20,21. Similarly, preterm UC-MSCs isolated from fetuses aborted at 8-12 weeks of gestation were reported to exhibit more vigorous proliferation and differentiation compared to term UC-MSCs isolated from newborns delivered at 37-40 weeks of gestation22. Despite the differences in gestational age and cord region, UC-MSCs isolated with this protocol also revealed a more vigorous proliferation of preterm UC-MSCs than term UC-MSCs12.
A critical step within this protocol is the UC dissection with purified enzyme blends that are composed of collagenase I and II and dispase. As outlined in the representative results, the stiffness of UC dramatically varied with gestational age (Figure 2). To achieve optimal dissection of UC, the incubation time of purified enzyme blends needs to be adjusted to the stiffness of the individual UC. Generally, it usually takes longer for term UC than preterm UC. Among existing methods to isolate MSCs from UC, we choose the enzymatic digestion method15 over the explant method14 that may lead to a longer culture cycle, lower yield, and earlier proliferation arrest17,18. An important modification of the enzyme digestion method is the use of purified enzyme blends instead of traditional collagenase, which enables an efficient and consistent dissection of UC from fetuses/infants with variable gestational ages.
A limitation of this protocol is the use of whole cord to isolate MSCs from UC. Because UC-MSCs can be isolated from all cord regions or whole cord13, UC-MSCs are isolated from whole cord in this protocol. This is due to the feasibility of UC dissection from preterm infants. However, the potential variation in the proportion of each cord region may limit the strict comparison between UC-MSCs isolated by this protocol.
UC-MSCs are being increasingly used as a source of mesenchymal stromal cells for preclinical and clinical studies8,9. Despite this increased usage, a consensus on methods of UC-MSCs isolation is still missing, which may result in different cell populations to be deemed the same UC-MSCs. This protocol will ultimately assist researchers in better understanding the derivation and functional characteristics of UC-MSCs.
The authors have nothing to disclose.
This work was supported by Grants-in-Aid for Scientific Research (C) (grant number: 25461644) and Young Scientists (B) (grant numbers: 15K19614, 26860845, 17K16298) of JSPS KAKENHI.
50mL plastic tube | AS One Coporation, Osaka, Japan | Violamo 1-3500-22 | |
12-well plate | AGC Techno Glass, Tokyo, Japan | Iwaki 3815-012 | |
60mm dish | AGC Techno Glass, Tokyo, Japan | Iwaki 3010-060 | |
Cell strainer (100 μm) | Thermo Fisher Scientific, Waltham, MA | Falcon 35-2360 | |
Cell strainer (70 μm) | Thermo Fisher Scientific, Waltham, MA | Falcon 35-2350 | |
Alpha MEM | Wako Pure Chemical, Osaka, Japan | 135-15175 | |
Fetal bovine serum | Sigma Aldrich, St. Louis, MO | 172012 | |
Reduced serum medium | Thermo Fisher Scientific, waltham, MA | OPTI-MEM Gibco 31985-070 | |
Antibiotic-antimycotic | Thermo Fisher Scientific, Waltham, MA | Gibco 15240-062 | |
Trypsin-EDTA | Wako Pure Chemical, Osaka, Japan | 209-16941 | |
PBS | Takara BIO, Shiga,Japan | T900 | |
Purified enzyme blends | Roche, Mannheim, Germany | Liberase DH Research Grade 05401054001 | |
PE-conjugated mouse primary antibody against CD14 | BD Bioscience, Franklin Lakes, NJ | 347497 | Lot: 3220644, RRID: AB_400312 |
PE-conjugated mouse primary antibody against CD19 | BD Bioscience, Franklin Lakes, NJ | 340364 | Lot: 3198741, RRID: AB_400018 |
PE-conjugated mouse primary antibody against CD34 | BD Bioscience, Franklin Lakes, NJ | 555822 | Lot: 3079912, RRID: AB_396151 |
PE-conjugated mouse primary antibody against CD45 | BD Bioscience, Franklin Lakes, NJ | 555483 | Lot: 2300520, RRID: AB_395875 |
PE-conjugated mouse primary antibody against CD73 | BD Bioscience, Franklin Lakes, NJ | 550257 | Lot: 3057778, RRID: AB_393561 |
PE-conjugated mouse primary antibody against CD90 | BD Bioscience, Franklin Lakes, NJ | 555596 | Lot: 3128616, RRID: AB_395970 |
PE-conjugated mouse primary antibody against CD105 | BD Bioscience, Franklin Lakes, NJ | 560839 | Lot: 4339624, RRID: AB_2033932 |
PE-conjugated mouse primary antibody against HLA-DR | BD Bioscience, Franklin Lakes, NJ | 347367 | Lot: 3219843, RRID: AB_400293 |
PE-conjugated mouse IgG1 k isotype | BD Bioscience, Franklin Lakes, NJ | 555749 | Lot: 3046675, RRID: AB_396091 |
PE-conjugated mouse IgG2a k isotype | BD Bioscience, Franklin Lakes, NJ | 555574 | Lot: 3035934, RRID: AB_395953 |
PE-conjugated mouse IgG2b k isotype | BD Bioscience, Franklin Lakes, NJ | 555743 | Lot: 3098896, RRID: AB_396086 |
Viability dye | BD Bioscience, Franklin Lakes, NJ | Fixable Viability Stain 450 562247 | |
Blocking reagent | Dainippon Pharmaceutical, Osaka, Japan | Block Ace UKB80 | |
FCM | BD Bioscience, Franklin Lakes, NJ | BD FACSAria III Cell Sorter | |
FCM software | BD Bioscience, Franklin Lakes, NJ | BD FACSDiva | |
Adipogenic differentiation medium | Invitrogen, Carlsbad, CA | StemPro Adipogenesis Differentiation kit A10070-01 | |
Osteogenic differentiation medium | Invitrogen, Carlsbad, CA | StemPro Osteogenesis Differentiation kit A10072-01 | |
Chondrogenic differentiation medium | Invitrogen, Carlsbad, CA | StemPro Chondrogenesis Differentiation kit A10071-01 | |
Formaldehyde | Polyscience, Warrigton, PA | 16% UltraPure Formaldehyde EM Grade #18814 | |
Oil Red O | Sigma Aldrich, St. Louis, MO | O0625 | |
Arizarin Red S | Sigma Aldrich, St. Louis, MO | A5533 | |
Toluidine Blue | Sigma Aldrich, St. Louis, MO | 198161 | |
Microscope | Keyence, Osaka, Japan | BZ-X700 |